Movement Alert｜HANSOH PHARMA Falls 3.16% in Regular Trading, Pharmaceutical Sector Broadly Weakens

Market Focus08-12 10:09

On August 12, HANSOH PHARMA fell 3.16% in regular trading, trading at HK$33.64/share, with turnover of HK$163 million. The decline came amid broad-based weakness across the pharmaceutical sector, partially retracing gains accumulated in the prior two sessions.

Within the Pharmaceuticals sector where HANSOH PHARMA belongs, individual stocks declined broadly. Among peers, ASYMCHEM fell 2.98%, HENGRUI PHARMA fell 2.17%, CF PHARMTECH fell 2.19%, CSPC PHARMA fell 2.07%, and SBP GROUP fell 1.80%.

The pullback follows a period of positive momentum for the stock. HANSOH PHARMA had risen approximately 4.92% on August 11 amid strength in innovative drug names and gained 3.65% on August 10 following clinical trial approval of its novel cholesterol-lowering drug HS-10582. CLSA maintains an Outperform rating with a HK$42 target price, anticipating five new drug approvals next year. The company is scheduled to release interim results on August 26.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1130874836?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-12 10:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130874836","market":"us","top_or_hot":-1,"title":"Movement Alert｜HANSOH PHARMA Falls 3.16% in Regular Trading, Pharmaceutical Sector Broadly Weakens","media":"Market Focus","content":"<p><p>On August 12, HANSOH PHARMA fell 3.16% in regular trading, trading at HK$33.64/share, with turnover of HK$163 million. The decline came amid broad-based weakness across the pharmaceutical sector, partially retracing gains accumulated in the prior two sessions.</p><p>Within the Pharmaceuticals sector where HANSOH PHARMA belongs, individual stocks declined broadly. Among peers, ASYMCHEM fell 2.98%, HENGRUI PHARMA fell 2.17%, CF PHARMTECH fell 2.19%, CSPC PHARMA fell 2.07%, and SBP GROUP fell 1.80%.</p><p>The pullback follows a period of positive momentum for the stock. HANSOH PHARMA had risen approximately 4.92% on August 11 amid strength in innovative drug names and gained 3.65% on August 10 following clinical trial approval of its novel cholesterol-lowering drug HS-10582. CLSA maintains an Outperform rating with a HK$42 target price, anticipating five new drug approvals next year. The company is scheduled to release interim results on August 26.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HANSOH PHARMA Falls 3.16% in Regular Trading, Pharmaceutical Sector Broadly Weakens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HANSOH PHARMA Falls 3.16% in Regular Trading, Pharmaceutical Sector Broadly Weakens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-12 10:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 12, HANSOH PHARMA fell 3.16% in regular trading, trading at HK$33.64/share, with turnover of HK$163 million. The decline came amid broad-based weakness across the pharmaceutical sector, partially retracing gains accumulated in the prior two sessions.</p><p>Within the Pharmaceuticals sector where HANSOH PHARMA belongs, individual stocks declined broadly. Among peers, ASYMCHEM fell 2.98%, HENGRUI PHARMA fell 2.17%, CF PHARMTECH fell 2.19%, CSPC PHARMA fell 2.07%, and SBP GROUP fell 1.80%.</p><p>The pullback follows a period of positive momentum for the stock. HANSOH PHARMA had risen approximately 4.92% on August 11 amid strength in innovative drug names and gained 3.65% on August 10 following clinical trial approval of its novel cholesterol-lowering drug HS-10582. CLSA maintains an Outperform rating with a HK$42 target price, anticipating five new drug approvals next year. The company is scheduled to release interim results on August 26.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1130874836","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130874836","pubTimestamp":1786500553,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 12, HANSOH PHARMA fell 3.16% in regular trading, trading at HK$33.64/share, with turnover of HK$163 million. The decline came amid broad-based weakness across the pharmaceutical sector,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"走势警报|豪森制药常规交易下跌3.16%，医药板块普遍走弱","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On August 12, HANSOH PHARMA fell 3.16% in regular trading, trading at HK$33.64/share, with turnover of HK$163 million. The decline came amid broad-based weakness across the pharmaceutical sector, partially retracing gains accumulated in the prior two sessions.Within the Pharmaceuticals sector where HANSOH PHARMA belongs, individual stocks declined broadly. Among peers, ASYMCHEM fell 2.98%, HENGRUI PHARMA fell 2.17%, CF PHARMTECH fell 2.19%, CSPC PHARMA fell 2.07%, and SBP GROUP fell 1.80%.The pullback follows a period of positive momentum for the stock. HANSOH PHARMA had risen approximately 4.92% on August 11 amid strength in innovative drug names and gained 3.65% on August 10 following clinical trial approval of its novel cholesterol-lowering drug HS-10582. CLSA maintains an Outperform rating with a HK$42 target price, anticipating five new drug approvals next year. The company is scheduled to release interim results on August 26.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1130874836","isCrawlerRequest":true}